July 2018- Although highly effective, high-intensity cytotoxic treatments for Burkitt lymphoma are available in resource-rich settings, these therapies are usually not feasible in SSA, and lower-intensity continuous infusion approaches are impractical. We review current treatment approaches in SSA and discuss options for risk stratification and individualize therapy.